Skip to main content

$0.075 0.003 (4.17%)

High

$0.08

Low

$0.07

Trades

22

Turnover

$32,042

Volume

431,146
30 June 2023 at 3:55pm
Register to track IMC and receive email alerts.
Subject
IMC Ann: Immuron Chairman Transition

IMC Ann: Letter to Shareholders

IMC Ann: Immuron CEO, Steven Lydeamore presents at LD Micro

IMC Ann: Immuron Initiates Recruitment of Travelan Clinical Study

IMC Ann: FDA Removed Clinical Hold on Campylobacter ETEC Therapeutic

IMC Ann: IMC CEO Steven Lydeamore to present at Coffee Microcaps

IMC Ann: Q3 FY23 Business Update Presentation

IMC Ann: Q3 FY23 Business Update Webinar

IMC Ann: Immuron Q3 Sales reach 150% of 1H Sales

IMC Ann: Notification of cessation of securities - IMC

IMC Ann: Appendix 4D and Half Year Report

IMC Ann: Business Update Presentation

IMC Ann: Immuron CEO Steven Lydeamore to host investor webinar

IMC Ann: Immuron and US NMRC respond to CampETEC FDA Clinical Hold

IMC Ann: US DOD Travelan Clinical Recruitment Milestone

IMC Ann: Immuron Receives European Patent on Drug Composition

IMC Ann: Change in substantial holding

IMC Ann: Immuron Receives FDA Approval for Travelan IND Application

IMC Ann: Immuron Submits IND Application To FDA for Travelan

IMC Ann: Amended Constitution

IMC Ann: Results of Annual General Meeting

IMC Ann: AGM Presentation

IMC Ann: Immuron completes strategic investment in Ateria Health

IMC Ann: Immuron CEO Steven Lydeamore to present at AusBioInvest

IMC Ann: Notice of Annual General Meeting/Proxy Form

IMC Ann: IMC investment in leading gut health biotech Ateria Health

IMC Ann: Immuron Executes Travelan Clinical Trial Agreement Pharmaron

IMC Ann: Appendix 4G

IMC Ann: Corporate Governance Statement

IMC Ann: Annual Report to shareholders

IMC Ann: FY22 Results and Business Update Presentation

IMC Ann: Appendix 4E and Preliminary Final Report

IMC Ann: Immuron CEO, Steven Lydeamore, to host an investor webinar

IMC Ann: Immuron Update on IMM-124E SARS-CoV-2 Research

IMC Ann: Update on IND Application for Campylobacter ETEC Therapeutic

IMC Ann: North American Travelan Sales up 494%, Global sales up 431%

IMC Ann: European Patent Notification on Drug Composition for CDI

IMC Ann: Change of Director's Interest Notice (DP)

IMC Ann: Notification regarding unquoted securities - IMC

IMC Ann: Change of Director's Interest Notice

IMC Ann: Notification of cessation of securities - IMC

IMC Ann: Notification of cessation of securities - IMC

IMC Ann: Change in substantial holding

IMC Ann: US DoD NMRC files IND application with FDA

IMC Ann: US DoD Uniformed Services University Clinical Update

IMC Ann: Appointment of Mr Steven Lydeamore as Chef Executive Officer

IMC Ann: Immuron Q3 Global Sales up 216% YoY

IMC Ann: Immuron new MTEC project proposal

IMC Ann: Initial Director's Interest Notice

IMC Ann: Appointment of Paul Brennan as Non-Executive Director

Register to track IMC and receive email alerts.

Similar Companies

CSL ...
CSL
CUV
IMM
IMU
MSB
OPT
PAR
PYC
RAC
TLX